This tiny drugmaker could give Pfizer an edge over its immuno-oncology competitors. Bristol-Myers Squibb (NYSE: BMY) and Merck‘s (NYSE:MRK)game-changing(NYSE:MRK)immuno-oncology drugs, Opdivo and Keytruda, respectively, have triggered an avalanche of research into so-called “checkpoint inhibitors” due to their stunning commercial success. For example, AstraZeneca, Pfizer (NYSE:PFE), and Roche have all made significant strides toward bringing their own checkpoint inhibitors to market […]